Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma

References

• Tsao MN Lloyd N Wong R Chow E Rakovitch E Laperriere N Whole brain radiotherapy for the treatment of multiple brain metastases Cochrane Database Syst Rev 19 2006 3 CD003869 16856022
   PubMedGoogle Scholar
• Kawabe T Phi JH Yamamoto M Kim DG Barfod BE Urakawa Y Treatment of brain metastasis from lung cancer Prog Neurol Surg 2012 25 148 155 22236676
   PubMedGoogle Scholar
• Kim JE Lee DH Choi Y Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis Lung Cancer 2009 65 3 351 354 19157632
   PubMed Web of Science ®Google Scholar
• Gounant V Wislez M Poulot V Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer Lung Cancer 2007 58 3 425 428 17945377
   PubMed Web of Science ®Google Scholar
• Olmez I Donahue BR Butler JS Huang Y Rubin P Xu Y Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis Lung Cancer 2010 70 2 174 179 20207442
   PubMed Web of Science ®Google Scholar
• Lind JS Lagerwaard FJ Smit EF Senan S Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer Int J Radiat Oncol Biol Phys 2009 74 5 1391 1396 19289264
   PubMed Web of Science ®Google Scholar
• Yi HG Kim HJ Kim YJ Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI Lung Cancer 2009 65 1 80 84 19059670
   PubMed Web of Science ®Google Scholar
• Trotti A Colevas AD Setser A CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 2003 13 3 176 181 12903007
   PubMed Web of Science ®Google Scholar
• Palazzi M Tomatis S Orlandi E Effects of treatment intensification on acute local toxicity during radiotherapy for head and neck cancer: prospective observational study validating CTCAE, version 3.0, scoring system Int J Radiat Oncol Biol Phys 2008 70 2 330 337 17881148
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA Therasse P Bogaerts J New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 2009 45 2 228 247 19097774
   PubMed Web of Science ®Google Scholar
• Sun JM Ahn MJ Park MJ Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors Lung Cancer 2010 69 1 105 109 19959251
   PubMed Web of Science ®Google Scholar
• Robinet G Thomas P Breton JL Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1 Ann Oncol 2001 12 1 59 67 11249050
   PubMed Web of Science ®Google Scholar
• Cortot AB Gerinière L Robinet G Groupe Lyon-Saint-Etienne d’Oncologie Thoracique Groupe Français de Pneumo-Cancérologie Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study Ann Oncol 2006 17 9 1412 1417 16790516
   PubMed Web of Science ®Google Scholar
• Guerrieri M Wong K Ryan G Millward M Quong G Ball DL A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung Lung Cancer 2004 46 1 107 111 15364138
   PubMed Web of Science ®Google Scholar
• Togashi Y Masago K Fukudo M Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer J Thorac Oncol 2010 5 7 950 955 20479691
   PubMed Web of Science ®Google Scholar
• Broniscer A Panetta JC O’Shaughnessy M Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 Clin Cancer Res 2007 13 5 1511 1515 17332296
   PubMed Web of Science ®Google Scholar
• O’Connor MM Mayberg MR Effects of radiation on cerebral vasculature: a review J Neurosurgery 2000 46 1 138 149
   Web of Science ®Google Scholar
• Hutchinson F Molecular biology of mutagenesis of mammalian cells by ionizing radiation Semin Cancer Biol 1993 4 2 85 92 8513151
   PubMed Web of Science ®Google Scholar
• Harms-Ringdahl M Nicotera P Radford IR Radiation induced apoptosis Mutat Res 1996 366 2 171 179 9001584
   PubMed Web of Science ®Google Scholar
• Chinnaiyan P Huang S Vallabhaneni G Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva) Cancer Res 2005 65 8 3328 3335 15833866
   PubMed Web of Science ®Google Scholar
• Halatsch ME Löw S Mursch K Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib. Laboratory investigation J Neurosurg 2009 111 2 211 218 19301967
   PubMed Web of Science ®Google Scholar
• Ciuleanu T Stelmakh L Cicenas S Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study Lancet Oncol 2012 13 3 300 308 22277837
   PubMed Web of Science ®Google Scholar
• Welsh JW Komaki R Amini A Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer J Clin Oncol 2013 31 7 895 902 23341526
   PubMed Web of Science ®Google Scholar
• Porta R Sánchez-Torres JM Paz-Ares L Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Eur Respir J 2011 37 3 624 631 20595147
   PubMed Web of Science ®Google Scholar